Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialEthan Basch, Deborah Schrag, Lauren J. Rogak et al.|Journal of Clinical Oncology|2015Cited by 2.6k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Ethan Basch, Deborah Schrag, Bryce B. Reeve et al.|JNCI Journal of the National Cancer Institute|2014Cited by 1.1k
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330